Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.60 |
| ▸ | HTR2A | P28223 | 16/20 | 0.41 |
| ▸ | HTR2B | P41595 | 16/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14094443 | 0.77 | HTR2C (0.59) | HTR2CHTR2AHTR2BLATS1GSK3B | |
| SCHEMBL1205270 | 0.77 | HTR2C (0.59) | HTR2CHTR2AHTR2BLATS1GSK3B | |
| SCHEMBL15985852 | 0.77 | ATR (0.49) | HTR2C | |
| SCHEMBL1026755 | 0.76 | HTR2C (1.00) | HTR2C | |
| SCHEMBL30297584 | 0.76 | HTR2C (1.00) | HTR2C | |
| SCHEMBL3683610 | 0.73 | HTR2C (0.41) | HTR2CHTR2AHTR2BLATS1GSK3B | |
| SCHEMBL3690829 | 0.72 | HTR2C (0.66) | HTR2CHTR2A | |
| SCHEMBL27581051 | 0.72 | GSK3B (0.39) | HTR2CHTR2AHTR2BLATS1GSK3B | |
| SCHEMBL27581053 | 0.72 | GSK3B (0.39) | HTR2CHTR2AHTR2BLATS1GSK3B | |
| SCHEMBL6177869 | 0.72 | HTR2A (0.44) | HTR2CHTR2AHTR2BLATS1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | claimed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR2C 14/4885HTR2A 12/4885HTR2B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.